Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Juan A. Garcia-Sanchez"'
Autor:
Lilla Szabó, Luca Adél Halmai, Erzsébet Ladányi, Juan Jose Garcia Sanchez, Salvatore Barone, Claudia Cabrera, Lise Retat, Laura Webber, István Wittmann, Boglárka Laczy
Publikováno v:
Frontiers in Nephrology, Vol 4 (2024)
ObjectivesThe Inside CKD programme implemented a microsimulation modelling approach to project the clinical and economic burden of chronic kidney disease (CKD) between 2024 and 2027 in Hungary.MethodsUsing the peer-reviewed Inside CKD microsimulation
Externí odkaz:
https://doaj.org/article/4bd75c1c749c4f5991bb65a09b6fe1f5
Autor:
Jacie T. Cooper, Andrew Lloyd, Juan Jose Garcia Sanchez, Elisabeth Sörstadius, Andrew Briggs, Phil McFarlane
Publikováno v:
Health and Quality of Life Outcomes, Vol 18, Iss 1, Pp 1-11 (2020)
Abstract Background A Task Force from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) provides recommendations on how to systematically identify and appraise health state utility (HSU) weights for cost-effectiveness analy
Externí odkaz:
https://doaj.org/article/597d59d5f6284504951d6b374f667c49
Autor:
Bartholomeus J. A. Willigers, Mario Ouwens, Andrew Briggs, Hiddo J. L. Heerspink, Carol Pollock, Roberto Pecoits-Filho, Navdeep Tangri, Csaba P. Kovesdy, David C. Wheeler, Juan Jose Garcia Sanchez
Publikováno v:
Advances in Therapy. 40:2741-2751
Autor:
Phil McEwan, Oliver Darlington, Ryan Miller, John J.V. McMurray, David C. Wheeler, Hiddo J.L. Heerspink, Andrew Briggs, Klas Bergenheim, Juan Jose Garcia Sanchez
Publikováno v:
Clinical Journal of the American Society of Nephrology, 17(12), 1730-1741. AMER SOC NEPHROLOGY
Background and objectives: CKD imposes a significant burden on patients and health care providers, particularly upon reaching kidney failure when patients may require KRT. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial d
Autor:
Carol Pollock, Glen James, Juan Jose Garcia Sanchez, Juan Jesus Carrero, Matthew Arnold, Carolyn S P Lam, Hungta (Tony) Chen, Stephen Nolan, Roberto Pecoits-Filho, David C Wheeler
Publikováno v:
Clinical Kidney Journal. 15:2124-2134
Background Chronic kidney disease (CKD) is widely reported to decrease quality of life, increase morbidity and mortality and cause increased healthcare resource utilisation (HCRU) as the disease progresses. However, there is a relative paucity of acc
Autor:
Juan Carlos Garcia-Monco, Aranzazu Gonzalo Garcia, Juan Manuel Garcia Sanchez, Maria Mar Martinez Vazquez, Ramon Muñoz Tena, Ana Isabel Olaldecoa Alonso, Goikoana Garmendia Saavedra, Joseba Iñaki Gallo Fernández, Maria Carmen Cairo Rojas, Roberto Abad Gar
Publikováno v:
International Journal of Integrated Care, Vol 19, Iss 4 (2019)
Introduction: Stroke remains the second leading cause of death around the globe, and the approach to stroke care has been deeply transformed in the last decades. Practice change implemented: The Hospital Universitario de Basurto (Basque country, Spai
Externí odkaz:
https://doaj.org/article/ece645bc8de641e49ec92d8f42f56e12
Autor:
Carol Pollock, Glen James, Juan Jose Garcia Sanchez, Matthew Arnold, Juan-Jesus Carrero, Carolyn S. P. Lam, Hungta Chen, Stephen Nolan, Roberto Pecoits-Filho
Publikováno v:
Advances in Therapy
Introduction Real-world data reporting healthcare resource utilisation and costs associated with end-of-life care for patients with chronic kidney disease (CKD) are limited. We examined length of hospitalisation and costs associated with end-of-life
Autor:
Jose Guzman-Parra, Carlos Gómez-Sánchez-Lafuente, Mónica García Medina, Carlos Aguilera-Serrano, Berta Moreno-Küstner, Verónica Hurtado-Melero, Juan A. Garcia-Sanchez, Antonio Bordallo-Aragón, Fermín Mayoral-Cleries
Background. To analyze the impact of the COVID-19 pandemic on mental health hospital admissions, the use of mechanical restraint and number of aggressions to the staff. Methods. Outcomes in the period from March 14, 2020–December 31, 2020 were comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74fcc30aaf50b2b19b506d57c966b000
https://doi.org/10.21203/rs.3.rs-2112556/v1
https://doi.org/10.21203/rs.3.rs-2112556/v1
Autor:
Navdeep Tangri, Salvatore Barone, Matthew Arnold, Juan Jose Garcia Sanchez, Cassandra Nan, Johan Bodegård
Publikováno v:
Metabolism. 142:155470
Autor:
Phil McEwan, Rebecca Boyce, Juan Jose Garcia Sanchez, C David Sjöström, Bergur Stefansson, Stephen Nolan, Ricardo Correa-Rotter, Peter Rossing, Glenn M Chertow, John J V McMurray, David C Wheeler, Hiddo J L Heerspink
Publikováno v:
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
Background The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in addition to standard therapy, in patients with chronic kidney disease (CKD) and albuminuria, and was